CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of August 28, 2026, CUE stock price declined to $27.88 with 100,905 million shares trading.

CUE has a beta of 3.78, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.08 to the broad based SPY ETF.

CUE has a market cap of $202.53 million. This is considered a Small Cap stock.

Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.

In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, DFAS, AVSC.

CUE has underperformed the market in the last year with a price return of +15.9% while the SPY ETF gained +19.7%. However, in the short term, CUE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +23.1% vs +2.2% return in SPY. But in the last 2 weeks, CUE shares have been beat by the market, returning -18.5% compared to an SPY return of -0.9%.

CUE support price is $25.80 and resistance is $30.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.